Shanghai Genechem Co., Ltd. (Genechem) Announces appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory board
PR88911
Shanghai Genechem Co., Ltd. (Genechem) Announces appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory board, and abstract presentation at AACR 2021 on Claudin 6 Ab and K-Ras TCR-T
SHANGHAI, April 8, 2021 /PRNewswire=KYODO JBN/ --
Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel
target discovery and development of novel therapeutics, today announced the
appointment of Dr. Eric Rowinsky, President and Executive Chairman of the Board
of Rgenix, Inc., and Dr. Manuel Hidalgo, Chief of Hematology and Medical
Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell
Medical Center, to its Scientific Advisory Board. Drs. Rowinsky and Hidalgo
will bring their strong expertise in translational and clinical development to
support Genechem's mission to bring its innovative pipeline to global markets
through novel target discovery, early development in China, and global
partnership.
Genechem also announces that it will present two abstracts at AACR 2021, on an
antibody against Claudin 6, and a TCR-T therapy against K-Ras mutations.
(https://www.abstractsonline.com/pp8/#!/9325/presentation/2600,
https://www.abstractsonline.com/pp8/#!/9325/presentation/1949)
"We are excited to welcome Drs. Rowinsky and Hidalgo, global leaders in
biopharma industry and translational/clinical development, to our SAB, as we
position Genechem to collaborate with cancer centers and biopharmaceutical
companies globally to advance development of its innovative pipeline developed
on our Good Research Practice (GRP) platform, leveraging CHAMP antibody
discovery platform and Cell Therapy Discovery platform", commented Yueqiong
Cao, Founder and CEO of Genechem.
"Genechem has built an innovative preclinical pipeline over the last five
years, building on almost 20 years of partnership with research Oncologists in
China, and I look forward to contributing my expertise to their mission of
bringing innovative medicine to patients and partners globally. I am also
impressed by their vision and global caliber management team, which I will
enjoy working with", Dr. Rowinsky remarked.
Dr. Rowinsky is currently serving on the Board of Directors for Biogen and as
President and Executive Chairman of RGenix, Inc. Dr. Rowinsky has also been the
Chief Scientific Officer of Clearpath Development Co., which rapidly advances
development stage therapeutic assets to pre-defined human proof-of-concept
milestones. Dr. Rowinsky was the Head of Research and Development and Chief
Medical Officer of Stemline Therapeutics, Inc., a biotechnology company
focusing on the discovery and development of therapeutics targeting cancer stem
cells. Dr. Rowinsky has also been an Adjunct Professor of Medicine at New York
University and has been an independent consultant from 2010-2019. Prior to
that, he was the Chief Executive Officer of Primrose Therapeutics, Inc., a
start-up biotechnology company focusing on the development of therapeutics for
polycystic kidney disease. From 2005 to December 2009 he served as the Chief
Medical Officer and Executive Vice President of ImClone Systems Incorporated, a
life sciences company. From 1996 to 2004 Dr. Rowinsky held several positions at
the Cancer Therapy & Research Center's Institute for Drug Development,
including Director of the Institute and Director of Clinical Research. During
that time, he held the SBC Endowed Chair for Early Drug Development and was
Clinical Professor of Medicine at the University of Texas Health Science Center
at San Antonio. From 1988 to 1996 Dr. Rowinsky was an associate professor of
oncology at the Johns Hopkins School of Medicine and on the staff of the Johns
Hopkins Hospital. Dr. Rowinsky is also a member of the Boards of Directors of
Fortress Biotech Inc., Purple Biotech Ltd. and Verastem, Inc., all of which are
biopharmaceutical companies.
"As a clinical oncologist involved in drug discovery and clinical trials, I'm
excited to bring my expertise to Genechem and help advance its antibody and
cell therapy platforms. I am pleased to support Genechem's global efforts in
advancing scientific understanding of cancer and addressing clinical unmet
needs, in particular in solid tumors," said Dr. Hidalgo, who receives an
honorarium for participation on Genechem's SAB.
Manuel Hidalgo, M.D., Ph.D.is currently the Chief of the Division of Hematology
and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill
Cornell Medical Center. He is also the Hugh E. Luckey Distinguished Professor
of Medicine and a senior member of the Sandra and Edward Meyer Cancer Center at
Weill Cornell Medicine. Dr. Hidalgo received his MD degree from the University
of Navarra in Pamplona, Spain in 1992 and a Ph.D. degree from University
Autonoma of Madrid in 1997. He trained in medicine and medical oncology at
Hospital ¨12 de Octubre¨ in Madrid and at the University of Texas Health
Science Center in San Antonio. He also completed a fellowship program in
anticancer drug development at the Institute of Drug Development in San
Antonio, TX. Prior to this position he served as an Assistant Professor of
Medicine at the Division of Hematology and Oncology at the University of Texas
Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns
Hopkins University to be Director of the Gastrointestinal Oncology Program at
the Kimmel Comprehensive Cancer Center at Johns Hopkins and Associate Professor
of Oncology. In 2009 he became Director of the Clinical Research Program at the
Spanish National Cancer Center and Vice director of Translational Research in
2011. In 2015 he became the Chief of the Division of Hematology and Oncology
and Director of the Rosenberg Clinical Cancer Center at the Beth Israel
Deaconess Medical Center in Boston. He was also the Theodore W. and Evenly G.
Berenson Professor of Medicine at Harvard Medical School. His main focus of
research has been new drug development in pancreatic cancer. His group
popularized the use of Avatar mouse models for cancer research and recently
contributed to the development and approval of nab-paclitaxel for pancreatic
cancer treatment. His current work focuses on strategies for personalized
medicine and immunotherapy in pancreatic cancer.
About Shanghai Genechem Co., Ltd. (Genechem)
Genechem is a leading innovation research company focused on target
discovery/validation, development of antibody and cell therapy products against
novel targets, and partnership globally to maximize its portfolio. Founded in
2002, now with over 500 employees, Genechem works closely with Research
Oncologists to translate clinical research into therapeutics addressing high
clinical unmet needs, leveraging its strong network of Research Oncologists in
over 300 hospitals and Good Research Practice (GRP platform) which includes
comprehensive RNAi library, tools including genetic typing, bioinformatic
analysis, genetic manipulation, as well as SOP and project management systems.
For more information, visit http://www.gcbio.com/.
Contact:
Dr. Tong Zhang
Chief Business Officer
Shanghai Genechem Co., Ltd
Tong.zhang@genechem.com.cn
+86-18501607878
SOURCE Shanghai Genechem Co., Ltd. (Genechem)
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。